AR and urinary bladder carcinoma: Ide et al., 2020 investigated the role of FOXO 1 in the carcinogenesis of bladder cancer in relation to the AR and observed that in non-neoplastic urothelial cells (SV-HUC) or bladder cancer cell lines, AR expression or dihydrotestosterone (DHT) treatment causes a downregulation of FOXO 1 gene and induced the inactivation of FOXO 1 through phosphorylation, FOXO 1 inactivation is correlated with the cell proliferation, migration and invasion of bladder cancer cells [56].